---
document_datetime: 2025-04-15 17:25:44
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tamiflu-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tamiflu-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1897511
conversion_datetime: 2025-12-15 00:12:55.027891
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Tamiflu

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - -     | 15/04/2025                          |                                             | Labelling and                    |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000247267   | Update of the package leaflet, section 'Instructions for the user', for Tamiflu 6 mg/ml powder for oral suspension, with improved text and image. Furthermore, the package leaflet was updated with revised contact details of local representatives and 'United Kingdom (Northern Ireland)' was deleted from the list of local representatives in line with the QRD template v10.4. Additionally, the MAH introduced changes to the prefixes for batch number in the labelling in compliance with QRD Appendix IV and to sections 2. and 6. in the package leaflet in line with the latest QRD template v10.4.   | PL   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|